ArticleActa dermato-venereologica2026
Standardizing Prurigo Control Assessment Globally: Linguistic Validation and Cross-cultural Adaptation of Prurigo Control Test in 18 Languages.
Article in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic prurigo (CPG), including prurigo nodularis (PN), is a neuroimmune-inflammatory skin condition characterized by persistent itching and fibrotic lesions. PN commonly affects older adults (>55 years) and imposes substantial disease burden, necessitating effective disease control. Prurigo Control Test (PCT) is the first validated, patient reported, disease control assessment test for PN/ CPG. To ensure broad accessibility and utility, cultural and linguistic adaptation of PCT is essential. We present the first comprehensive translation initiative of PCT into 18 widely spoken languages, beyond its original German and English versions: Arabic/Chinese (Simplified)/ Chinese (Traditional)/Czech/Danish/Dutch/Finnish/ French/Hebrew/Icelandic/Italian/Japanese/Korean/ Norwegian/Portuguese/Spanish/Swedish/Turkish. We followed best translation practices recommen ded by ISPOR, EMA and FDA ‒ conceptual analysis, forward/backward translation, author review, cognitive interviews, proofreading and finalization. The availability of PCT in multiple languages facilitates its global applicability and empowers physicians/caregivers/patients to assess the PN/CPG control using PCT in their preferred language, thereby enhancing implementation of this test across diverse clinical and cultural settings. The goal of translating this academically developed test while ensuring broader demographic representation (ages 18-80, diverse educational and occupational backgrounds) is to facilitate meaningful conversations between physicians and patients and optimize treatment decisions while transcending language barriers. To our knowledge, PCT is the first disease control assessment test specifically designed for PN/CPG to undergo such extensive linguistic adap-tation, contributing to the advancement of global dermatological assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.